Wayne Carter President and CEO KCALSI KCALSI Stakeholders

Wayne Carter President and CEO, KCALSI

KCALSI Stakeholders

Draft for Discussion Purposes Regional Life Science Strategy and Vision Strategy Vision Statement The Kansas City region is a global leader at the nexus of human and animal health benefiting all our citizens and the economy. Cross-Cutting Capabilities Collaboration Workforce Development Capital Formation 3 Messaging & Marketing

1 Data Draft for Discussion Purposes Strategy Interoperable database of animal health data built on the Cerner FHIR platform to enable linkage to human data and translational medicine HUMAN ANIMAL Cross-Cutting Capabilities Collaboration Workforce Development Capital Formation Gerald Wyckoff, Ph. D. UMKC Messaging & Marketing Debbie Kirchhoff, MBA Kansas State - Olathe Majid Jaberi-Douraki, Ph. D. Jim Riviere, DVM, Ph. D. , DSc(hon) Kansas State University 4

Draft for Discussion Purposes “The Kansas City region is developing a value-based collaborative healthcare ecosystem to establish Kansas City as The Outcomes Research Region” Healthcare Ecosystem Pilot Project: Percutaneous Coronary Intervention (Coronary Angioplasty) Engage Hospital Systems 5

Draft for Discussion Purposes Percutaneous Coronary Intervention 12% 11% 10% 9% 8% 7% 6% 5% 4% 3% 2% 1% 0% 2 main risks: bleeding and acute kidney injury Q 1 Q 2 Q 3 Q 4 Q 1 201120112012201220132013201420142015 SAVE $10, 667 9% Avoidance of one in-hospital acute kidney injury following PCI. 1 8% SAVE $8, 658 3% Avoidance of one in-hospital major bleeding event following PCI. 2 1% Cath. PCI Bleeding Rates 7% 6% 5% 4% 2% 0% Q 3 2012 Q 4 2012 Q 1 2013 Q 2 2013 Q 3 2013 Q 4 2013 Q 1 2014 Acute Kidney Injury Rates 6

Draft for Discussion Purposes Current Status Adopted e. PRISM • • Saint Luke’s Health System Stormont Vail Truman Medical Center University of Missouri Considering e. PRISM • • Lawrence Memorial Hospital University of Kansas Hospital VA Hospital Via Christi Change management – driving adoption Follow-on programs AEG accelerator 7 Not interested • HCA • Mosaic Hospital • North Kansas City

Draft for Discussion Purposes HUMAN ANIMAL Regional Comparative Oncology Program Strategy Veterinary oncologist with appointments at: KSU, MU, KU and CMH Facilitate a comparative and translational oncology program Cisplatin-Hyaluronan Human Proof of Concept in clientowned dogs with spontaneous tumors Canine – Pivotal blinded trial 150 dogs Collaboration Cross-Cutting Capabilities Workforce Development Capital Formation Human – Phase 1, Non-resectable, treatment resistant head and neck Squamous Cell Carcinoma 8 Messa

Draft for Discussion Purposes Neurodevelopmental Neurodegeneration Autism Healthy Aging Health IT/Outcomes Research Approach Strategy Large longitudinal study to Developing and linking consistent understand the effects of diet and diagnostic methods Cross-Cutting Capabilities exercise/life style on healthy aging to and cognition Effective treatment methods Collaboration Workforce Development Capital Formation Messaging & Marketing to Deliver better outcomes for ASD patients 9

Draft for Discussion Purposes Collaboration Strategy …a program designed to stimulate regional scientific collaboration Design: • Session Cancer Immunotherapy C 2 C ran from Sept – Dec 2016 $50, 000 grant for regional collaborative research awarded to 2 • presenters speaking for 15 minutes followed by Q/A: Guangfu Li, University of Missouri 1) What problem are you trying to solve? 2) What unique approach/technology are you applying to the • Mitochondrial problem? Dysfunction C 2 C ran from April – August 2017 $50, 000 granthave for regional collaborative research awarded to 3) • What results you collected? Dr. Baki Agbas, Kansas City might University 4) What types of collaboration you be interested in developing? 5) What problems do you need solved? 10

HUMAN ANIMAL Neoantigen-specific effector T cells therapy for osteosarcoma and B-cell lymphoma in dogs Clinical Study: pediatric high-grade glioma

Strategy …a program designed to stimulate regional scientific collaboration Next Collaborate 2 Cure… - Starting in April 2018 – Clinical Outcomes Research …improving the quality and value of patient care • • Once a month event 2 hours of presentations followed by networking 15 min presentations by Outcomes Researchers Reverse pitches by Providers and Payers describing their “Pain points”

Draft for Discussion Purposes Workforce Development Life Sciences Talent to Industry Exchange Strategy Life Sciences TIE Process completed in November 2016 Life Sciences TIE work plan: Regional Advisory Council – “Platform Technology” • Bioinformatics – Curriculum Development • Contract Research Organizations – Stackable Credentials Experiential Learning Task Force 13

Draft for Discussion Purposes 2017 KCALSI Research Grant Program Strategy • Three, $50, 000 research grants for Outcomes Research Blue Cross Blue Shield Kansas City (Next RFP September 2018) • Three, $50, 000 research grants for Childhood Genetic Diseases Paul Patton Trust, BOA (Next RFP March 2018) • Five, $50, 000 research grants for Nexus of Human and Animal Medicine Hall Family Foundation (Next RFP July 2018) • Two, $50, 000 research grants for Collaborate 2 Cure KCALSI General Funds Every $1 brings over $9. 10 back to your research institutions and our community in federal grant funds! 14

Draft for Discussion Purposes Vision Statement The Kansas City region is a global leader at the nexus of human and animal health benefiting all our citizens and the economy. Cross-Cutting Capabilities Collaboration Workforce Development 15 Capital Formation Messaging & Marketing

Draft for Discussion Purposes 2018 Events Collaborate 2 Cure - Outcomes April KC Bioinformatics Conference April 11 – 12 Columbia, MO One Health Research Symposium August 19 – 20 Kansas City, MO Annual Dinner September Kansas City, MO KC Global One Health Day November 1 Kansas City 16